A research team with Mayo Clinic investigators has developed a new technology addressing the drawbacks of CT-based lung cancer tests showing false positive results. These results are accessible in PLOS One.
Tobias Peikert, M.D. and a pulmonologist, Mayo Clinic, stated that most challenging issue in lung cancer screening is that majority of positive test results for the cancer screenings are the false positive. And even, 96% of nodules in people with the danger of lung cancer are not nodules of cancer.
Further, he explained that the false positive screening results may put the significant patient in anxiety. It often procures for additional tests and surgery, which are unnecessary and increase the cost of healthcare. All these consequences may lead to injuries and mortality, which are unintended by the physicians.
Dr. Peikert and Fabien Maldonado, Vanderbilt University, with their associates, employed a radio mics approach to tackle the challenge of false positive tests in the screening of lung cancer. This approach helps to study the lung cancer CT images, which were analyzed as part of the National Lung Cancer Screening Trial.
Radiomics extracts huge quantitative data from medical images. It also uses computer programs to detect the characteristics of the disease, which cannot be seen by the naked eye.
A set of about 57 variables were tested for shape, volume, nodule density & surface characteristics, and texture of the surrounding lung tissue. About eight variables were identified by the researchers, which helped them to differentiate in between benign nodule and a cancerous nodule.
The results disclosed that all of the eight variables were not linked directly to the nodule size. Static variables such as past cancer history, smoking status, and age were not included as a part of their testing.
Researchers from Australia have announced a new drug for the treatment of an aggressive form of breast cancer. The treatment starves the cancer cells of nutrients and stops their multiplication.
Clinical trials will be started within the next few years once they are successful in the lab. This treatment is supposed to offer a hope for women diagnosed with triple-negative breast cancer, which accounts for around 15% of all breast cancer cases. This cancer has typically poorer survival outcomes.